Peptide vehicle drives Crispr delivery of Cas9 into cells
Gene editing enzyme ferried via endocytic pathway
Scientists in Spain have put forward what they describe as the first non-covalent strategy for delivering the Crispr Cas9 ribonucleoprotein into cells.